Interferon-beta1

Biologic (subtype unspecified)

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

No registered studies of this drug's own program.

Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT04079088 · Biogen
2021-06-30 – 2024-09-18 · Relapsing Multiple Sclerosis
What this study did

Competitive landscape

7 other tracked programmes target this mechanism.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Interferon-Beta1: this drugStage not on recordBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary
Interferon Alfa-2b (Intron A)
Approved(overall)
Biologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
Interferon Beta-1b
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorPartial signal
NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS
NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed
Peginterferon Alfa-2a (Pegasys)
Approved(overall)
—Type I interferon receptorPartial signal
NCT00006164: Long-term peginterferon did not reduce the rate of disease progression vs no treatment in chronic hepatitis C with advanced fibrosis missed
Peginterferon Beta-1a (Plegridy)
Approved(overall)
Biologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)Reliable signal
NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481)
NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037).
Rebif (interferon Beta 1a)
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorWeak signalFeatured results are non-efficacy only
Ropeginterferon Alfa-2b (Besremi)
Approved(overall)
Protein / enzyme therapeuticType I interferon receptorPartial signal
NCT04285086: Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide
Human Serum Albumin / Interferon Alpha2b Fusion Protein
Phase 1/2(overall)
Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary

Upcoming events

No upcoming readouts on record for this asset.